CN203647775U - Human immunodeficiency virus specificity plasma adsorption column - Google Patents
Human immunodeficiency virus specificity plasma adsorption column Download PDFInfo
- Publication number
- CN203647775U CN203647775U CN201420024837.5U CN201420024837U CN203647775U CN 203647775 U CN203647775 U CN 203647775U CN 201420024837 U CN201420024837 U CN 201420024837U CN 203647775 U CN203647775 U CN 203647775U
- Authority
- CN
- China
- Prior art keywords
- adsorption column
- immunodeficiency virus
- human immunodeficiency
- hiv
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims abstract description 127
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 125
- 229920000669 heparin Polymers 0.000 claims abstract description 58
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229960002897 heparin Drugs 0.000 claims abstract description 56
- 239000011347 resin Substances 0.000 claims abstract description 43
- 229920005989 resin Polymers 0.000 claims abstract description 43
- 239000002245 particle Substances 0.000 claims abstract description 42
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 24
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 8
- 210000002381 plasma Anatomy 0.000 claims description 67
- 239000008280 blood Substances 0.000 claims description 54
- 210000004369 blood Anatomy 0.000 claims description 51
- 239000002253 acid Substances 0.000 claims description 20
- 239000011148 porous material Substances 0.000 claims description 7
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 238000003466 welding Methods 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000004083 survival effect Effects 0.000 abstract description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 description 17
- 239000008187 granular material Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000005611 electricity Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229940000351 hemocyte Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 238000005202 decontamination Methods 0.000 description 3
- 230000003588 decontaminative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108700004025 env Genes Proteins 0.000 description 3
- 101150030339 env gene Proteins 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- -1 intergrase Proteins 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 101710114816 Gene 41 protein Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 108700026222 vpu Genes Proteins 0.000 description 2
- 101150090490 vpu gene Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108010013534 Auxilins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100023922 Putative tyrosine-protein phosphatase auxilin Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 101150059019 vif gene Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 101150024249 vpr gene Proteins 0.000 description 1
- 101150040614 vpx gene Proteins 0.000 description 1
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model relates to the field of medical instruments, in particular to a human immunodeficiency virus specificity plasma adsorption column, which comprises an adsorption column cavity and resin particles which are arranged in the adsorption column cavity and are made from macroporous strong alkaline styrene anion exchange resins, a lithium heparin layer is adhered on the inner wall of the adsorption column cavity, the thickness of the lithium heparin layer is 0.5-1mm, a plurality of adsorption holes are distributed on the resin particles, the aperture of each adsorption hole is 120.5nm, and the two ends of the adsorption column cavity are respectively communicated with blood vessels. The human immunodeficiency virus specificity plasma adsorption column can achieve selective adsorption, and effectively clears up plasma of human immunodeficiency virus patients, thereby being capable of greatly improving survival rate of the human immunodeficiency virus patients, and prolonging and rescuing life of the human immunodeficiency virus patients.
Description
Technical field
This utility model relates to medical instruments field, in particular to a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column.
Background technology
HIV (human immunodeficiency virus) is HIV (human immunodeficiency virus).
HIV (human immunodeficiency virus) (Human Immunodeficiency Virus, HIV), as the term suggests it can cause the defect of human immunity system.1981, HIV (human immunodeficiency virus) was found first in the U.S..It is a kind of slow virus (Lentivirus) that infects human immunity system cells, belongs to the one of retrovirus retrovirus.So far without the effective mortality infectious disease of therapy.This virus is destroyed the immunocompetence of human body, causes immune system to lose resistance, thereby causes various diseases and cancer to be able to survive in human body, develops into finally, causes acquired immune deficiency syndrome (AIDS) (acquired immune deficiency syndrome (AIDS)).
Virus present situation: worldwide caused nearly 1,200 ten thousand people's death, exceeded 3,000 ten thousand people and be infected.
On July 25th, 1986, the World Health Organization's releasing bulletin, ICTV's meeting determines, HIV (human immunodeficiency virus) is renamed as to HIV (human immunodeficiency virus) (Human Immunodeficiency Virus), is called for short HIV.
In 2004, the whole world estimated at the existence together of 3590 to 4,430 ten thousand person to person's para-immunity defective viruss, and wherein 430 to 6,400,000 Genus Homos, in emerging infectious diseases example, in addition, have 280 to 3,500,000 people to die from acquired immune deficiency syndrome (AIDS).These numerals in constantly increasing, wherein, the regional amounts of increase such as East Asia, Eastern Europe, the Central Asia are the fastest.Infecting the most serious area and remain Sub-Saharan Africa, is secondly South Asia and Southeast Asia.
Morphosis: HIV (human immunodeficiency virus) diameter 120 nanometers, roughly spherical in shape.Outer virionic membrane is lipoid peplos, from host cell, and the virulent albumen gp120 of embedding and gp41; Gp41 is transmembrane protein, and gp120 is positioned at surface, and is combined by noncovalent interaction with gp41.Inwardly the sphere matrix (Matrix) being formed by albumen p17, and the half-cone capsid (Capsid) of albumen p24 formation, capsid is high electron density under Electronic Speculum.Capsid includes virulent rna gene group, enzyme (reverse transcriptase, intergrase, protease) and other compositions from host cell (as tRNAlys3, as the primer of reverse transcription).
Gene code: viral genome is two identical positive chain RNAs, and every RNA is about 9.2-9.8kb.Two ends are long terminal repeat (long terminal repeats, LTR), containing cis regulating and controlling sequence, control proviral expression.Having proved has promoter and enhancer and contains negative regulation district at LTR.Sequential coding between LTR at least 9 albumen, can be divided three classes: structural protein, modulin, auxilin.
Can the encode polymerization precursor protein of approximately 500 aminoacid composition of 1.gag gene, forms P17 through protease hydrolysis, and P24 nucleoprotein, makes RNA not destroyed by extraneous nuclease.
2.Pol gene code polymerase precursor protein, forms protease, intergrase, reverse transcriptase, ribonuclease H through cutting, is virus multiplication institute essential.
Approximately 863 amino acid whose precursor proteins of 3.env gene code glycosyl change into gp160, gp120 and gp41.During gp120 contains and antigenic determinant, proved in HIV and epitope, on gp120V3 ring, V3Huan district is the critical function district of envelope protein, in virus and cell fusion, plays an important role.Gp120 is connected with non-covalent bond with transmembrane protein gp41.Gp41 and target cell are merged, and impel in cell entry cell.Experiment shows that gp41 also has compared with strong antigen, can induce and produce antibody response.
4.TaT gene coded protein can be combined with LTR, to increase viral all genetic transcription rates, also can after transcribing, promote the translation of virus mRNA.
5.Rev gene outcome is a kind of cis-activating factor, can suppress order (Cis-Acting repression sequance, Crs) removal of inhibit function to cis acting in env and gag, strengthens the expression of gag and env gene, to synthesize corresponding virus structural protein.
6.Nef gene coded protein P27 has negative regulation effect to the expression of HIV gene, to postpone virus replication.This albumen acts on the LTR of HIv cDNA, suppresses the virus transcription of integrating.May be that HIV maintains that to continue sense collective institute essential in vivo.
7.Vif gene pairs HIV is not essential, but may affect generation and the interior propagation of body of free HIV infectivity, virion.
8.VPU gene by HIV-1 peculiar, to HIV effectively copy and the assembling of virion with ripe indispensable.
9.Vpr gene coded protein is a kind of weak transcriptional activator, plays a role in vivo in the breeding cycle.
HIV-2 gene structure and HIV-1 have difference: it does not contain VPU gene, but has a function to fail to understand VPX gene.Nucleic acid hybridization checks the nucleotide sequence of HIV-1 and HIV-2, and only 40% is identical.The antibody no cross reaction that env gene expression product excitating organism produces.
HIV (human immunodeficiency virus) spreads by constantly copying original virus protein in the process of diffusion, the thinking of this research treatment acquired immune deficiency syndrome (AIDS) be in cut-out blood HIV (human immunodeficiency virus) copy former.HIV (human immunodeficiency virus) is to be mainly present in blood of human body, and the ground of other existence is respectively seminal fluid, vaginal secretions, saliva, milk, cerebrospinal fluid etc. even, but not long in these local time-to-live.All can finally all can get back in blood at any body fluid; HIV (human immunodeficiency virus) is mainly also to complete constantly and copy in blood.Accomplish in one move so the HIV (human immunodeficiency virus) in blood is adsorbed and filter out just.It is slower that HIV (human immunodeficiency virus) copies relative adsorption filtration, and through repeatedly repeatedly adsorbing and filtering, final HIV (human immunodeficiency virus) can all be removed, and greatly improves the survival rate of HIV sufferers, delays, saves patient's life-span.
A kind of HIV (human immunodeficiency virus) affinity adsorption column is disclosed in number of patent application 201210118840, this adsorption column can by the HIV (human immunodeficiency virus) in blood with together with the useful albumen of human body, adsorb, in treatment, affect the absorption of patient to nutrient substance, cause patient at treatment health in mid-term because can not get enough nutritional supplementation, and reduced the immunity of self.
Utility model content
The purpose of this utility model is to provide a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column, to solve the above problems.
A kind of HIV (human immunodeficiency virus) specificity plasma adsorption column providing in embodiment of the present utility model, comprising: adsorption column cavity and being located in described adsorption column cavity, the resin particle of being made up of macroporous strong basic styrene series anion exchange resin;
On the inwall of described adsorption column cavity, with Lithium acid heparin layer, the thickness of described Lithium acid heparin layer is 0.5-1mm;
On described resin particle, be distributed with multiple adsorption holes, the pore size of each described adsorption hole is 120.5nm;
The two ends of described adsorption column cavity are communicated with respectively blood catheter.
A kind of HIV (human immunodeficiency virus) specificity plasma adsorption column that this utility model provides, in a cavity, be provided with the resin particle of being made by macroporous strong basic styrene series anion exchange resin, this resin particle band basic group is positive electricity, HIV (human immunodeficiency virus) is with negative electricity, and the resin particle that is positive electricity with basic group can be by electronegative HIV (human immunodeficiency virus) absorption.Resin absorption granule is provided with multiple adsorption holes simultaneously, the pore size of these adsorption holes is 120.5nm, for being slightly larger than the diameter of HIV (human immunodeficiency virus) granule, this resin absorption granule can be limited and only be adsorbed HIV (human immunodeficiency virus) granule by electrical and pore size thus, the granule that is not HIV (human immunodeficiency virus) for other can not adsorb, and the HIV (human immunodeficiency virus) specificity plasma adsorption column that namely this utility model provides can be realized optionally absorption.
Heparin is a kind of anticoagulant, is the polymer being alternately formed by connecting by two kinds of polysaccharide, has in vivo and in vitro blood coagulation resisting function.Lithium acid heparin is conventional anticoagulant heparin agent, and the sodium of heparin, potassium, lithium, ammonium salt are wherein best with Lithium acid heparin.On the inwall of adsorption column cavity, evenly with Lithium acid heparin layer, the heparin compositions in Lithium acid heparin layer is a kind of mucopolysaccharide that contains sulfate group, and with powerful negative charge, same sex electric charge repels each other, and can prevent that electronegative virus is attached to the inwall of adsorption column cavity; Can inhale mutually with the macroporous strong basic styrene series anion exchange resin adsorption particle of positively charged again, form the barrier being combined as a whole more closely and ensure more effectively viral adsorption simultaneously.Moreover, because heparin has the effect that stops thrombin to form, thereby stop platelet aggregation, so can make blood plasma can not form thrombosis in adsorption column; In addition, other adsorption column, in the used time, necessarily need to rush in advance multipass with heparin solution its heparinization could be used, also need, to injecting a certain amount of heparin in patient body, to make patient's whole body heparinization, and this adsorption column all entirely exempt from, both can anticoagulation, again can be in order to avoid punching be in advance used simple.In sum, the Heterosis that has added the adsorption column of Lithium acid heparin obtains dripping showing fully.
When use this utility model to provide HIV (human immunodeficiency virus) specificity plasma adsorption column time, first start blood extracorporeal circulation purifier normal saline blood catheter and this adsorption column rinsed one time, and then start and enter the purging in vitro circulation pattern of blood plasma.Draw blood out from human body artery, use plasma separator that blood is separated, blood is divided into visible component---hemocyte, as: erythrocyte, leukocyte, platelet etc. and aeriform part---blood plasma.Visible component as, in the direct feedback bodies such as erythrocyte, leukocyte, platelet, and aeriform part---blood plasma, the blood catheter being communicated with by this adsorption column cavity one end enters in adsorption column, through resin absorption granule, by the HIV (human immunodeficiency virus) absorption in blood plasma, the blood catheter being communicated with by the adsorption column cavity other end more afterwards feeds back human vein.When the cyclic process of blood plasma purging in vitro, directly inject heparin solution by transfusion device in to blood catheter in dosing place of the three-way valve of the nearly arterial end on blood vessel road, for anticoagulant.
First the blood of drawing from human body artery undertaken blood separation by plasma separator, visible component hemocyte wherein, as, erythrocyte, leukocyte, in the direct feedback bodies such as platelet, the blood catheter that aeriform part blood plasma is communicated with by this adsorption column cavity one end enters in adsorption column, through resin absorption granule, the HIV (human immunodeficiency virus) in blood plasma is adsorbed, the blood catheter being communicated with by the adsorption column cavity other end more afterwards feeds back human vein, realize the specific selective absorption of adsorption column for HIV (human immunodeficiency virus), make HIV (human immunodeficiency virus) patient's blood plasma obtain cleaning effectively.
And because be evenly equipped with Lithium acid heparin on this utility model adsorption column inwall, removed from the past other adsorption column will from low concentration heparin solution be flushed in advance high concentration heparin solution rush in advance some all over making the loaded down with trivial details of its heparinization, so also become very simple in operation.
Simultaneously in plasma purification cyclic process, directly inject heparin solution by transfusion device in to blood catheter in dosing place of the three-way valve of the nearly arterial end on blood vessel road, this heparin solution is that about 500mL normal saline is joined 80mg heparin sodium and is mixed, and blood catheter transfusion drip speed is adjusted to approximately 30 droplets/minute.Pre-washing pipe road and adsorption column so repeatedly, also need not give first dose of heparin amount of injection in patient body, allow patient's whole body heparinization, also need not append heparin, this process approximately can be saved 35 to 40 minutes times before the decontamination cycle of blood plasma, and blood plasma extracorporeal circulation on one side, adds heparin on one side, giving first dose than conventional heparin, then to append the method in clinical application of a certain amount of heparin every half an hour more accurate, more efficient.
This using method is only applicable to this adsorption column, because this adsorption column is the adsorption column that has added Lithium acid heparin, exempts from pre-punching.
Brief description of the drawings
The structural representation of a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column that Fig. 1 provides for this utility model;
The sectional view of a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column that Fig. 2 provides for this utility model;
1. adsorption column cavity, 2. resin particle, 3. drainage screen, 4. seal cover, 5. blood plasma gateway, 6. blood catheter.
Detailed description of the invention
Also by reference to the accompanying drawings this utility model is described in further detail below by specific embodiment.
Embodiment 1: as depicted in figs. 1 and 2,
A kind of HIV (human immunodeficiency virus) specificity plasma adsorption column, comprising: adsorption column cavity 1 and be located in described adsorption column cavity 1 resin particle 2 of being made up of macroporous strong basic styrene series anion exchange resin;
On the inwall of described adsorption column cavity 1, with Lithium acid heparin layer, the thickness of described Lithium acid heparin layer is 0.5-1mm;
On described resin particle 2, be distributed with multiple adsorption holes, the pore size of each described adsorption hole is 120.5nm;
The two ends of described adsorption column cavity 1 are communicated with respectively blood catheter 6.
A kind of HIV (human immunodeficiency virus) specificity plasma adsorption column that this utility model provides, in a cavity, be provided with the resin particle 2 of being made by macroporous strong basic styrene series anion exchange resin, this resin particle is resin absorption granule, band basic group is positive electricity, HIV (human immunodeficiency virus) is with negative electricity, and the resin particle 2 that is positive electricity with basic group can be by electronegative HIV (human immunodeficiency virus) absorption.Resin absorption granule is provided with multiple adsorption holes simultaneously, the pore size of these adsorption holes is 120.5nm, for being slightly larger than the diameter of HIV (human immunodeficiency virus) granule, this resin absorption granule can be limited and only be adsorbed HIV (human immunodeficiency virus) granule by electrical and pore size thus, the granule that is not HIV (human immunodeficiency virus) for other can not adsorb, and the HIV (human immunodeficiency virus) specificity plasma adsorption column that namely this utility model provides can be realized optionally absorption.
Heparin is a kind of anticoagulant, is the polymer being alternately formed by connecting by two kinds of polysaccharide, has in vivo and in vitro blood coagulation resisting function.Lithium acid heparin is conventional anticoagulant heparin agent, and the sodium of heparin, potassium, lithium, ammonium salt are wherein best with Lithium acid heparin.On the inwall of adsorption column cavity 1, evenly has Lithium acid heparin layer, heparin compositions in Lithium acid heparin layer is a kind of mucopolysaccharide that contains sulfate group, with powerful negative charge, same sex electric charge repels each other, and can prevent that electronegative virus is attached to the inwall of adsorption column cavity 1; Can inhale mutually with the macroporous strong basic styrene series anion exchange resin adsorption particle of positively charged again, form the barrier being combined as a whole more closely and ensure more effectively viral adsorption simultaneously.Moreover, because heparin has the effect that stops thrombin to form, thereby stop platelet aggregation, so can make blood plasma can not form thrombosis in adsorption column; In addition, other adsorption column, in the used time, necessarily need to make its heparinization with heparin solution preliminary filling multipass, but also need to give a certain amount of heparin of injection in patient body, and this adsorption column all entirely exempt from, not only can anticoagulation but also can be in order to avoid punching is in advance used simple.In sum, the Heterosis that has added the adsorption column of Lithium acid heparin obtains dripping showing fully.
When use this utility model to provide HIV (human immunodeficiency virus) specificity plasma adsorption column time, first start blood extracorporeal circulation purifier normal saline blood catheter 6 and this adsorption column rinsed one time, and then the decontamination cycle pattern that starts and enter blood plasma.Draw blood out from human body artery, use plasma separator that blood is separated, blood is divided into visible component---hemocyte, as: erythrocyte, leukocyte, platelet etc. and aeriform part--blood plasma.Visible component as, in the direct feedback bodies such as erythrocyte, leukocyte, platelet, the blood catheter 6 that aeriform part blood plasma is communicated with by this adsorption column cavity 1 one end enters in adsorption column, through resin absorption granule, the HIV (human immunodeficiency virus) in blood plasma is adsorbed, the blood catheter 6 being communicated with by adsorption column cavity 1 other end more afterwards feeds back human vein. when the cyclic process of blood plasma purging in vitro in dosing place of the three-way valve of the nearly arterial end on blood vessel road directly by transfusion device to the interior injection heparin solution of blood catheter 6, for anticoagulant.
First the blood of drawing from human body artery undertaken blood separation by plasma separator, visible component hemocyte wherein as, erythrocyte, leukocyte, in the direct feedback bodies such as platelet, the blood catheter 6 that aeriform part blood plasma is communicated with by this adsorption column cavity 1 one end enters in adsorption column, through resin absorption granule, the HIV (human immunodeficiency virus) in blood plasma is adsorbed, the blood catheter 6 being communicated with by adsorption column cavity 1 other end more afterwards feeds back human vein, realize the specific selective absorption of adsorption column for HIV (human immunodeficiency virus), HIV (human immunodeficiency virus) patient's blood plasma has obtained cleaning effectively.
And because be evenly equipped with Lithium acid heparin on this utility model adsorption column inwall, removed from the past other adsorption column will from low concentration heparin solution be flushed in advance high concentration heparin solution rush in advance some all over making the loaded down with trivial details of its heparinization, so also become very simple in operation.
Simultaneously in plasma purification cyclic process, in dosing place of the three-way valve of the nearly arterial end on blood vessel road directly by transfusion device to the interior injection heparin solution of blood catheter 6, this heparin solution is that about 500mL normal saline is joined 80mg heparin sodium and is mixed, and blood catheter 6 transfusion drip speeds are adjusted to approximately 30 droplets/minute.Pre-washing pipe road and adsorption column so repeatedly, also need not give first dose of heparin amount of injection in patient body, allow patient's whole body heparinization, also need not append heparin, this process approximately can be saved front 35 to 40 minutes times of decontamination cycle of blood plasma, and blood plasma extracorporeal circulation on one side, adds heparin on one side, giving first dose than conventional heparin, then to append the method in clinical application of a certain amount of heparin every half an hour more accurate, more efficient.
This using method is only applicable to this adsorption column, because this adsorption column is the adsorption column that has added Lithium acid heparin, exempts from pre-punching.
Embodiment 2:
According to above-described embodiment, this utility model has also done following improvement:
The two ends of described adsorption column cavity 1 are provided with blood plasma can be passed through, the intransitable drainage screen 3 of described resin particle 2 and seal cover 4, and described seal cover 4 is provided with blood plasma gateway 5;
Described drainage screen 3 is wrapped in the two ends of described adsorption column cavity 1, and described seal cover 4 is located at the outermost at the two ends of described adsorption column cavity 1, and the outer wall of the inwall of described seal cover 4 and described adsorption column cavity 1 is tightly connected; Described blood catheter 6 is communicated with described blood plasma gateway 5 respectively.
For in processing adsorption column cavity 1, resin particle 2 can be packed in adsorption column cavity 1, what adsorption column cavity 1 can be sealed is fine simultaneously, establish seal cover 4 at the two ends of adsorption column cavity 1, seal cover 4 is provided with blood plasma gateway 5, by this blood plasma gateway 5, the two ends of adsorption column cavity 1 are communicated with respectively blood catheter 6.
Can realize in plasma purification process in order to make adsorption column cavity 1, adsorption particle wherein can not dropped out, the two ends of adsorption column cavity 1 are provided with blood plasma can be by, the intransitable drainage screen 3 of resin particle 2, described drainage screen 3 is wrapped in the two ends of described adsorption column cavity 1, described seal cover 4 is located at the outermost at the two ends of described adsorption column cavity 1, and the outer wall of the inwall of described seal cover 4 and described adsorption column cavity 1 is tightly connected.
In order to reach good adsorption efficiency, preferably, the cumulative volume that resin particle 2 is set is more than or equal to 1/2 of described adsorption column cavity 1 volume.
The particle diameter of each described resin particle 2 is identical.More closely neat for what can make to arrange between multiple resin particles 2, the particle diameter that each resin particle 2 can be set is identical.
Resin particle 2 is layered distribution.The particle diameter that resin particle 2 also can be set is larger, makes resin particle 2 be layered distribution.
Each resin particle 2 is uniform round shaped grain or even side grain.Preferably, for convenient processing, each resin particle 2 is set and is uniform round shaped grain.Each resin particle 2 also can be set and be uniform side's grain.Or the resin particle 2 that is other any shape all can.
The inwall welding of the blood plasma gateway 5 arranging on blood catheter 6 and seal cover 4.In order to improve the seal being connected between adsorption column cavity 1 and blood catheter 6, the inwall welding of the blood plasma gateway 5 on outer wall and the adsorption column cavity 1 of blood catheter 6 can be set.
The inwall of blood plasma gateway 5 is provided with for twisting with blood catheter 6 binding thread connecing.For can be at the initial stage that blood catheter 6 is set, loose blood catheter 6 can not come off easily, can on the inwall of blood plasma gateway 5, be provided for and blood catheter 6 is twisted the binding thread connecing.At the connection initial stage, by this binding thread, fastening the twisting of blood catheter 6 and blood plasma gateway 5 connect, carry out again afterwards welding.
The foregoing is only preferred embodiment of the present utility model and with, be not limited to this utility model, for a person skilled in the art, this utility model can have various modifications and variations.All within spirit of the present utility model and principle, any amendment of doing, be equal to replacement, improvement etc., within all should being included in protection domain of the present utility model.Any imitate, change on the aperture of absorbent particles all belongs to infringement.
Claims (8)
1. a HIV (human immunodeficiency virus) specificity plasma adsorption column, is characterized in that, comprising: adsorption column cavity and being located in described adsorption column cavity, the resin particle of being made up of macroporous strong basic styrene series anion exchange resin;
On the inwall of described adsorption column cavity, with Lithium acid heparin layer, the thickness of described Lithium acid heparin layer is 0.5-1mm;
On described resin particle, be distributed with multiple adsorption holes, the pore size of each described adsorption hole is 120.5nm;
The two ends of described adsorption column cavity are communicated with respectively blood catheter.
2. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 1, is characterized in that,
The two ends of described adsorption column cavity are provided with blood plasma can be passed through, the intransitable drainage screen of described resin particle and seal cover, and described seal cover is provided with blood plasma gateway;
Described drainage screen is wrapped in the two ends of described adsorption column cavity, and described seal cover is located at the outermost at the two ends of described adsorption column cavity, and the outer wall of the inwall of described seal cover and described adsorption column cavity is tightly connected; Described blood catheter is communicated with described blood plasma gateway respectively.
3. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 1, is characterized in that, the cumulative volume of described resin particle is more than or equal to 1/2 of described adsorption column cavity volume.
4. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 1, is characterized in that, the particle diameter of each described resin particle is identical.
5. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 1, is characterized in that, described resin particle is layered distribution.
6. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 1, is characterized in that, each described resin particle is uniform round shaped grain or even side grain.
7. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 2, is characterized in that, the inwall welding of described blood catheter and described blood plasma gateway.
8. a kind of HIV (human immunodeficiency virus) specificity plasma adsorption column according to claim 2, is characterized in that, the inwall of described blood plasma gateway is provided with for twisting with blood catheter the binding thread connecing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420024837.5U CN203647775U (en) | 2014-01-15 | 2014-01-15 | Human immunodeficiency virus specificity plasma adsorption column |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420024837.5U CN203647775U (en) | 2014-01-15 | 2014-01-15 | Human immunodeficiency virus specificity plasma adsorption column |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203647775U true CN203647775U (en) | 2014-06-18 |
Family
ID=50914220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420024837.5U Expired - Lifetime CN203647775U (en) | 2014-01-15 | 2014-01-15 | Human immunodeficiency virus specificity plasma adsorption column |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203647775U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103691016A (en) * | 2014-01-15 | 2014-04-02 | 倪自谦 | Aids virus specific plasma adsorption column and application method thereof |
| CN106267414A (en) * | 2016-07-01 | 2017-01-04 | 翁炳焕 | Acquired immune deficiency syndrome (AIDS) immunologic purging device |
-
2014
- 2014-01-15 CN CN201420024837.5U patent/CN203647775U/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103691016A (en) * | 2014-01-15 | 2014-04-02 | 倪自谦 | Aids virus specific plasma adsorption column and application method thereof |
| CN106267414A (en) * | 2016-07-01 | 2017-01-04 | 翁炳焕 | Acquired immune deficiency syndrome (AIDS) immunologic purging device |
| CN106267414B (en) * | 2016-07-01 | 2019-02-19 | 翁炳焕 | AIDS immunologic purging device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103691016A (en) | Aids virus specific plasma adsorption column and application method thereof | |
| RU2353399C2 (en) | Method of isolating virus from blood by lectin hemodialysis | |
| US5484396A (en) | Method and device for treatment of HIV infections and AIDS | |
| DE69929986T2 (en) | METHOD FOR REMOVING HIV AND OTHER VIRUSES FROM BLOOD | |
| Rumpf et al. | Association of ethylene-oxide-induced IgE antibodies with symptoms in dialysis patients | |
| US20110218512A1 (en) | Enhanced antiviral therapy methods and devices | |
| US20160000987A1 (en) | Device and method for purifying virally infected blood | |
| CN102600521A (en) | Device and method for eliminating pathogens in blood | |
| Uemura et al. | Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin | |
| Tullis et al. | Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients | |
| US10155947B2 (en) | Method for inhibiting Ebola virus via miRNA | |
| CN203647775U (en) | Human immunodeficiency virus specificity plasma adsorption column | |
| CN107987173A (en) | Double target spot Chimeric antigen receptors, its encoding gene, have the gene plasmid, immune T effector cell and HIV-1 applications | |
| WO2010033514A1 (en) | Methods for reducing viral load of hepatitus c virus in hemodialysis patients | |
| CN203677610U (en) | HCV specificity plasma adsorption column | |
| Fabrizi et al. | Hepatitis B virus infection in dialysis patients | |
| CN106267410B (en) | HIV infection cell separator | |
| CN210844570U (en) | Dual plasma exchange device | |
| CN203763561U (en) | HBV (hepatitis B virus) specific plasma adsorption column | |
| CN103721307A (en) | Hepatitis C virus specificity plasma adsorption column and using method thereof | |
| CN107974460A (en) | Chimeric antigen receptor gene for HIV-1, plasmid, T cell, kit and application with the gene | |
| CN203647776U (en) | Hepatitis D virus absorber | |
| CN106178162B (en) | Treating AIDS organelle | |
| CN106110422B (en) | AIDS immunization therapy absorber | |
| CN201821963U (en) | Novel anti-virus mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20140618 |
|
| CX01 | Expiry of patent term |